Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Open accessThe DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Abstract
The synaptic vesicle glycoprotein SV2A belongs to the major facilitator superfamily (MFS) of transporters and is an integral constituent of synaptic vesicle membranes. SV2A has been demonstrated to be involved in vesicle trafficking and exocytosis, processes crucial for neurotransmission. The anti-seizure drug levetiracetam was the first ligand to target SV2A and displays a broad spectrum of anti-seizure activity in various preclinical models. Several lines of preclinical and clinical evidence, including genetics and protein expression changes, support an important role of SV2A in epilepsy pathophysiology. While the functional consequences of SV2A ligand binding are not fully elucidated, studies suggest that subsequent SV2A conformational changes may contribute to seizure protection. Conversely, the recently discovered negative SV2A modulators, such as UCB0255, counteract the anti-seizure effect of levetiracetam and display procognitive properties in preclinical models. More broadly, dysfunction of SV2A may also be involved in Alzheimer's disease and other types of cognitive impairment, suggesting potential novel therapies for levetiracetam and its congeners. Furthermore, emerging data indicate that there may be important roles for two other SV2 isoforms (SV2B and SV2C) in the pathogenesis of epilepsy, as well as other neurodegenerative diseases. Utilization of recently developed SV2A positron emission tomography ligands will strengthen and reinforce the pharmacological evidence that SV2A is a druggable target, and will provide a better understanding of its role in epilepsy and other neurological diseases, aiding in further defining the full therapeutic potential of SV2A modulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Mechanism of action of clinically approved anti-seizure drugs. Updated and modified from Löscher and Schmidt [151]. Drugs marked with asterisks indicate that these compounds act by multiple mechanims (not all mechanisms shown here). GABA-T GABA aminotransferase, GAT GABA transporter, SV2A synaptic vesicle protein 2A, GABA gamma-aminobutyric acid, NMDA N-methyl-D-aspartate, AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, KCNQ a family of voltage-gated potassium channels (also known as the Kv7 family)](https://figures.cochat.ai/paper-figures/694be75c144240faa7c6d22e54f6d22c/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-1.jpg)

![Fig. 3 Effect of LEV on the a MEST in non-kindled rats, and b threshold for secondarily generalized seizures in amygdala-kindled rats. c, d Effect of BRV and SEL on the GST in amygdala-kindled rats. Data are shown as means ± SEM of a 20 non-kindled and b–d 9 fully kindled rats in percentage seizure threshold increase above vehicle control seizure thresholds. Significant differences to control thresholds are indicated by an asterisk (p < 0.05). Note the marked difference in anti-seizure efficacy of LEV in a non-kindled vs. b kindled rats. All drugs also significantly increased the threshold for focal seizures (ADT) in kindled rats. The minimum doses significantly increasing ADT were 1.25 mg/kg (LEV), 0.68 mg/kg (BRV), and 0.0074 mg/kg (SEL). Data on MEST in non-kindled rats are taken from Löscher and Hönack [12], and data on kindled rats are from Potschka and Löscher (unpublished observations). LEV levetiracetam, MEST maximal electroshock seizure threshold, GST generalized seizure threshold, BRV brivaracetam, SEL seletracetam, SEM standard error of the mean, ADT after-discharge threshold, i.p. intraperitoneally](https://figures.cochat.ai/paper-figures/55eccfdd82394651ae3440d7035152a8/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-3.jpg)
![Fig. 4 Correlation between the anti-seizure activity of a series of LEV analogs in different epilepsy models and their SV2A in vitro binding affinities. a Genetically sound-susceptible mice; b corneally kindled mice; c rats with spontaneous absence-like EEG seizures from the GAERS strain. SV2A binding affinities pIC50 (−logIC50) were measured in rat brain membranes with the use of [3H]ucb 30889. Protective potencies, based on dose-response studies, are shown as pED50 (−logED50). All correlations were statistically significant (p < 0.01). From Kaminski et al. [20]. LEV levetiracetam, EEG electroencephalogram, GAERS genetical absence epilepsy rats from Strasbourg, SV2A synaptic vesicle protein 2A. ED 50median effective dose, IC 50half maximal inhibitory concentration, pED 50 logED50, pIC 50 logIC50](https://figures.cochat.ai/paper-figures/4f0d15f761d9459d8c5439926e35bb2f/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-4.jpg)
![Fig. 5 Schematic representation of the dynamics of SVs at the presynaptic terminal, illustrating detailed mechanism of NT release and synaptic vesicle recycling. SVs are specialized spheroidal membrane structures that traffic along the axon to the presynaptic terminals, where they internalize and store NTs (blue dots). The SV membrane harbors proteins, some of them highly glycosylated (synapsin, synaptotagmin, SV2, and synaptophysin), whose precise sorting is required for an efficient neurotransmission. A magnified view of an SV (top left) shows the main identified vesicular proteins (except for the proton pump). Some SV proteins, such as synapsins or SV2s, come in multiple isoforms. Once SVs are loaded by NTs, a number of processes lead to excocytosis. (1) NT-loaded SVs dock to the presynaptic membrane by interaction of Rab3 with the RIM protein. Docking displays the SVs in close contact with the SNARE ternary complex (syntaxin 1, SNAP25, and VAMP) and SNARE effectors (MUNCs). (2) Preactivation (priming). In response to increased presynaptic concentrations of Ca2+, sensed by synaptophysin, proteins of the complex change conformation, inducing SVs to fuse with the plasma membrane and release their contents into the synaptic cleft. (3) Fusion/release. Subsequently, empty SVs undergo coating with clathrin polymers, and dynamin-driven scission from plasma membrane. (4) Coating/scission allows SV membrane proteins to be recycled. SV2s are thought to be involved in several of these processes, including calcium-dependent exocytosis, NT loading/retention in synaptic vesicles, and synaptic vesicle priming, as well as transport of vesicle constituents. Updated and modified from Rossetto et al. [23]. SVs synaptic vesicles, NT neurotransmitter, SV2 synaptic vesicle protein-2, Syt synaptotagmin, VAMP vesicle integral membrane protein, SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptor, RIM proteins a family of active zone proteins, SNAP25 synaptosomal-associated protein 25, MUNC mammalian uncoordinated proteins, ADP adenosine diphosphate, ATP adenosine triphosphate](https://figures.cochat.ai/paper-figures/f67babb58fbf42a39c0f5376d3d7cc09/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-5.jpg)
![Fig. 6 Schematic representation of SV2A. a SV2A is comprised of 2 TM domains (each of which is comprised of 6 TM helices) and three extramembranous domains, namely the amino domain (blue); a long intervening loop spanning region between TM helices 6 and 7 (orange); and an extracellular domain between TM helices 7 and 8 (green). 2D protein topology figure generated using Protter [152]. Models of b inward-open (based on GlpT template) and c outward-open (based on FucP) conformations of the SV2A protein [86] aligned using the numbering system for proteins of the major facilitator superfamily [153]. TM transmembrane, 2D 2-dimensional, SV2A synaptic vesicle protein-2A, GlpT glycerol-3-phosphate transporter, FucP L-fucose-proton symporter](https://figures.cochat.ai/paper-figures/b1bb645587184654a6c1a9e8d0fc52b7/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-6.jpg)
![Fig. 7 Characterization of a novel SV2A PET radiotracer [11C]UCB-J in humans. a Axial, coronal and sagittal brain MRI images in a healthy volunteer subject (top row); regional volume of distribution maps (VT) during test (middle row) and retest (bottom row) PET scanning with [11C]UCB-J in the same subject. b Axial and coronal brain MRI images in a patient with temporal lobe epilepsy (top row); standardized uptake value maps (SUV) of [11C]UCB-J in the same subject (bottom row). Arrows show unilateral mesial temporal sclerosis (MTS) seen on MRI (top row) and reduced radioligand binding in the corresponding areas of the right mesial temporal lobe of the same subject (bottom row). From Finnema et al. [55]. SV2A synaptic vesicle protein-2A, PET positron emission tomography, MRI magnetic resonance imaging, SUV standardized uptake value, MTS mesial temporal sclerosis, V T volume of distribution](https://figures.cochat.ai/paper-figures/0632327ab6974cc299df1559444b130b/synaptic-vesicle-glycoprotein-2a-ligands-in-the-treatment-of-epilepsy-and-beyond-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Through these convergent actions, SV2A functions as a molecular scaffold that stabilizes presynaptic terminals while postsynaptic strengthening consolidates [175,184,198].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [175]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across models of stress, epilepsy, and neurodegeneration, modulation of SV2A preserves synaptic structure and maintains transmission after plasticity induction [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [175]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Functionally, SV2A modulation limits the slide from induced plasticity to maladaptive remodeling and relapse-like behavior [175,199,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [175]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This places SV2A at the center of synaptic resilience, linking vesicle dynamics to durable circuit integrity in health and disease [173,175,195].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [175]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Levetiracetam restores vesicle fusion fidelity, rescues basal transmission, and normalizes synaptic protein composition, effects that depend on direct SV2A engagement and extend to hippocampal volume and plasticity recovery [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [175]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J. H., & Abeliovich, A. (2013) · Nature · doi:10.1038/nature12415 · Cited by 171
RetractedEarly Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204 · cited 1×
“patients who did not respond to previous ASDs are more likely to demonstrate pharmacoresistance to additional ASD treatment regimens [127, 128].”
BackgroundThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“In 2003, the molecular nature of LBS was discovered and identified as the synaptic vesicle glycoprotein 2A (SV2A) [6].”
BackgroundProtter: interactive protein feature visualization and integration with experimental proteomic data
Omasits, U., Ahrens, C. H., Müller, S., & Wollscheid, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt607 · Cited by 1,347 · cited 1×
“2D protein topology figure generated using Protter [152].”
MethodThe neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1430 · Cited by 1,239 · cited 1×
“This involves modulation of voltage-gated ion channels, enhancement of c-aminobutyric acid (GABA)-mediated inhibition, interactions with elements of the synaptic release machinery, or blockade of ionotropic glutamate receptors [4, 5].”
BackgroundSelf-citationThe descriptive epidemiology of epilepsy—A review
Banerjee, P. N., Filippi, D., & Allen Hauser, W. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.03.003 · Cited by 929 · cited 1×
“Epilepsy is the most common neurological condition affecting individuals of all ages and a cause of substantial morbidity and mortality [1, 2].”
BackgroundReduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment
Bakker, A., Krauss, G. L., Albert, M. S., Speck, C. L., Jones, L. R., Stark, C. E., Yassa, M. A., Bassett, S. S., Shelton, A. L., & Gallagher, M. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.023 · Cited by 908 · cited 2×
“cantly improved [60], substantiating previous experiments with levetiracetam in a rat model of age-related memory loss [61].”
BackgroundResultChang, B. S., & Lowenstein, D. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022308 · Cited by 731
Buckley, K., & Kelly, R. B. (1985) · The Journal of cell biology · doi:10.1083/jcb.100.4.1284 · Cited by 712 · cited 1×
“SV2, one of the first synaptic vesicle proteins identified, is a component of all vertebrate synaptic vesicles [25].”
BackgroundNew avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 675
Self-citationSanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G.-Q., Palop, J. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121081109 · Cited by 638 · cited 1×
“Levetiracetam treatment of APP transgenic mice has similarly been reported to improve cognitive function, whereas other anti-seizure agents fail to do so [63].”
BackgroundBotulinum neurotoxins: genetic, structural and mechanistic insights
Rossetto, O., Pirazzini, M., & Montecucco, C. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3295 · Cited by 634
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy
Barton, M. E., Klein, B. D., Wolf, H. H., & Steve White, H. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00302-3 · Cited by 613 · cited 18×
“In a critical review on the role of SV2A for the effects of levetiracetam, Surges et al. [81] concluded in 2008 that ‘‘although levetiracetam shares some targets with other ASDs, levetiracetam exhibits unique mechanisms of action and a novel and unique binding site’’.”
BackgroundMethodInfluentialImaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575
Sudhof, T. C., & Rizo, J. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005637 · Cited by 510
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506 · cited 1×
“Scientists at UCB continued to test levetiracetam in various animal models, including acute, chronic, and genetic models of seizures or epilepsy, and data from these experiments (Table 1) further confirming a unique profile of levetiracetam consisting of a broad spectrum of efficacy in animal models of acquired and ge…”
BackgroundSelf-citationDifferential expression of synaptic vesicle protein 2 (SV2) isoforms
Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440 · cited 4×
“In contrast to SV2A, SV2B has a more restricted expression pattern; however, it is widely coexpressed with SV2A in many, but not all, synaptic vesicles of nerve terminals, including the hippocampal pyramidal cells [27, 28].”
BackgroundInfluentialAbnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 4×
“Although the mechanisms of SV2A function are not fully understood, a reduction in SV2A expression appears to lead to abnormal neurotransmission and the development of seizures [34, 36].”
BackgroundResultInfluentialLöscher, W., & Brandt, C. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003046 · Cited by 414 · cited 3×
“Thus, levetiracetam was found to exert antiepileptogenic or disease-modifying effects in SERs [143, 144], indicating that studies on kindling acquisition may be more predictive for such effects than data from SE models, and that post-SE studies may lead to false negative data on antiepileptogenic drug potential [139].”
BackgroundResultSelf-citationSV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release
Janz, R., Goda, Y., Geppert, M., Missler, M., & Südhof, T. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)81046-6 · Cited by 367
Löscher, W., Hönack, D., & Rundfeldt, C. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37251-9 · Cited by 343 · cited 4×
“Therefore, these data indicated that levetiracetam did not simply mask the expression of kindled seizures through an anti-seizure effect but exerted a true disease-modifying effect [15].”
BackgroundMethodInfluentialSelf-citationDiagnosing refractory epilepsy: response to sequential treatment schedules
Mohanraj, R., & Brodie, M. J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01215.x · Cited by 340 · cited 1×
“patients who did not respond to previous ASDs are more likely to demonstrate pharmacoresistance to additional ASD treatment regimens [127, 128].”
BackgroundMechanisms of Action of Antiseizure Drugs and the Ketogenic Diet
Rogawski, M. A., Löscher, W., & Rho, J. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022780 · Cited by 336 · cited 3×
“in calcium-dependent exocytosis, neurotransmitter loading/ retention in synaptic vesicles, and synaptic vesicle priming, as well as transport of vesicle constituents [5].”
BackgroundSelf-citationGorter, J. A., van Vliet, E. A., Aronica, E., Breit, T., Rauwerda, H., Lopes da Silva, F. H., & Wadman, W. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-06.2006 · Cited by 316 · cited 3×
“[37] were the first to describe that SV2A gene”
BackgroundNabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168179 · Cited by 296 · cited 3×
“Its whole body biodistribution was studied in non-human primates, demonstrating high uptake and fast kinetics in the brain [78].”
BackgroundInfluentialLöscher, W., & Hönack, D. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90768-d · Cited by 281 · cited 29×
“These and other findings triggered UCB Pharma to commission Löscher, in 1989, to perform a further characterization of the anti-seizure efficacy of levetiracetam in the amygdala kindling model, a predictive rat model of temporal lobe epilepsy (TLE) [12].”
BackgroundMethodResultInfluentialSelf-citationThe synaptic vesicle protein SV2 is a novel type of transmembrane transporter
Feany, M. B., Lee, S., Edwards, R. H., & Buckley, K. M. (1992) · Cell · doi:10.1016/0092-8674(92)90319-8 · Cited by 260 · cited 1×
“By sequence homology, SV2A has been described as a member of the Major Facilitator Superfamily (MFS) of transporters [32, 82, 83] and is considered to adopt the architecture found in the X-ray crystallography of the”
BackgroundSV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
Bajjalieh, S. M., Peterson, K., Shinghal, R., & Scheller, R. H. (1992) · Science · doi:10.1126/science.1519064 · Cited by 256 · cited 2×
“The latter is supported by homology with the major facilitator superfamily (MFS) of membrane transport proteins [32] and by the suggestion that SV2A is a galactose transporter [33].”
BackgroundNoyer, M., Gillard, M., Matagne, A., Hénichart, J.-P., & Wülfert, E. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00436-o · Cited by 255 · cited 2×
“In 1993, pioneering studies at UCB Pharma led to the identification of a specific binding site for [(3)H]-levetiracetam, which became known as the levetiracetam binding site (LBS), preferentially localized on synaptic plasma membranes with high prevalence in a number of brain structures, including the hippocampus, cor…”
BackgroundSelf-citationBiton, V., Berkovic, S. F., Abou‐Khalil, B., Sperling, M. R., Johnson, M. E., & Lu, S. (2014) · Epilepsia · doi:10.1111/epi.12433 · Cited by 253
Gillard, M., Fuks, B., Leclercq, K., & Matagne, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.064 · Cited by 253 · cited 3×
“Brivaracetam displays a 15- to 30-fold higher affinity to SV2A than levetiracetam and is selective for SV2A [8, 9].”
BackgroundSelf-citationAnimal models of intractable epilepsy
Löscher, W. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00035-x · Cited by 244 · cited 1×
“This model was discovered by evaluating the anti-seizure effect of phenytoin in large groups of kindled rats, resulting in three subgroups—responders, non-responders, and variable responders (cf, [46]).”
MethodSelf-citationLevetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures
Noachtar, S., Andermann, E., Meyvisch, P., Andermann, F., Gough, W. B., & Schiemann-Delgado, J. (2008) · Neurology · doi:10.1212/01.wnl.0000297512.18364.40 · Cited by 242 · cited 1×
“Several randomized, double-blind, placebo-controlled studies in idiopathic generalized epilepsies have shown a significant response of myoclonic seizures to levetiracetam treatment, and the drug is approved by the EMA and FDA as add-on treatment of juvenile myoclonic epilepsy [117, 118].”
BackgroundKlein, P., Schiemann, J., Sperling, M. R., Whitesides, J., Liang, W., Stalvey, T., Brandt, C., & Kwan, P. (2015) · Epilepsia · doi:10.1111/epi.13212 · Cited by 239 · cited 1×
“Interestingly, a post hoc analysis of trial data from a recent major clinical study with brivaracetam [116] on the impact of levetiracetam exposure suggests seizure reduction in patients never exposed to levetiracetam as well as those previously exposed to levetiracetam, although the effect appeared to be greater in t…”
Ryvlin, P., Werhahn, K. J., Blaszczyk, B., Johnson, M. E., & Lu, S. (2014) · Epilepsia · doi:10.1111/epi.12432 · Cited by 231
Kenda, B. M., Matagne, A. C., Talaga, P. E., Pasau, P. M., Differding, E., Lallemand, B. I., Frycia, A. M., Moureau, F. G., Klitgaard, H. V., Gillard, M. R., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030913e · Cited by 226 · cited 1×
“properties superior to levetiracetam [96].”
Self-citationProgress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.09.005 · Cited by 225 · cited 3×
“The terminal half- life of brivaracetam is approximately 8 h and does not varywith dose [101].”
BackgroundInfluentialMatagne, A., Margineanu, D., Kenda, B., Michel, P., & Klitgaard, H. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.198 · Cited by 224 · cited 1×
“In this context, it is noteworthy that the selective, highaffinity SV2A ligand brivaracetam shows more pronounced antiepileptogenic effects than levetiracetam in kindling models in mice [108].”
BackgroundSelf-citationCumbo, E., & Ligori, L. D. (2010) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2010.01.015 · Cited by 216 · cited 2×
“In a prospective, randomized, case-control study of AD patients with seizures, treatment with either levetiracetam, phenobarbital, or lamotrigine exhibited the same efficacy to suppress seizures, but, in addition, treatment with levetiracetam was associated with improved cognitive performance, specifically improved at…”
BackgroundJanz, R., & Südhof, T. C. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00370-x · Cited by 213 · cited 1×
“SV2C displays an even more restricted pattern of expression, which, under physiological conditions, is mainly limited to basal ganglia and the brain stem [29, 30].”
Backgrounducb L059, a novel anti-convulsant drug: pharmacological profile in animais
Gower, A. J., Noyer, M., Verloes, R., Gobert, J., & Wülfert, E. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90855-x · Cited by 212
Brain contains two forms of synaptic vesicle protein 2.
Bajjalieh, S. M., Peterson, K., Linial, M., & Scheller, R. H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2150 · Cited by 197 · cited 2×
“In contrast to SV2A, SV2B has a more restricted expression pattern; however, it is widely coexpressed with SV2A in many, but not all, synaptic vesicles of nerve terminals, including the hippocampal pyramidal cells [27, 28].”
BackgroundGrønborg, M., Pavlos, N. J., Brunk, I., Chua, J. J. E., Münster-Wandowski, A., Riedel, D., Ahnert-Hilger, G., Urlaub, H., & Jahn, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4074-09.2010 · Cited by 194
Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy
Silver, J. M., Shin, C., & McNamara, J. O. (1991) · Annals of Neurology · doi:10.1002/ana.410290404 · Cited by 184 · cited 1×
“The only other ASD, for which a similar effect had been described previously, was high-dose treatment with valproate [133], whereas other ASDs just retarded kindling by their suppressive effect on kindled seizures [134].”
BackgroundGuidelines for EEG in encephalopathy related to ESES/CSWS in children
Scheltens‐de Boer, M. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02211.x · Cited by 179
Kaminski, R. M., Matagne, A., Leclercq, K., Gillard, M., Michel, P., Kenda, B., Talaga, P., & Klitgaard, H. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.11.021 · Cited by 169
Self-citationKoh, M. T., Haberman, R. P., Foti, S., McCown, T. J., & Gallagher, M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.207 · Cited by 169 · cited 1×
“cantly improved [60], substantiating previous experiments with levetiracetam in a rat model of age-related memory loss [61].”
ResultNicolas, J., Hannestad, J., Holden, D., Kervyn, S., Nabulsi, N., Tytgat, D., Huang, Y., Chanteux, H., Staelens, L., Matagne, A., et al. (2016) · Epilepsia · doi:10.1111/epi.13267 · Cited by 169 · cited 5×
“04), leading to a higher brain–blood barrier permeability of brivaracetam [98].”
BackgroundInfluentialSelf-citationKlitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168 · cited 10×
“Brivaracetam also differs from levetiracetam by its selective, high affinity and differential interaction with SV2A [9].”
BackgroundResultInfluentialSelf-citationIs amygdala kindling in rats a model for drug-resistant partial epilepsy?
Löscher, W., Jäckel, R., & Czuczwar, S. J. (1986) · Experimental Neurology · doi:10.1016/0014-4886(86)90160-3 · Cited by 164 · cited 2×
“This was in sharp contrast to the profile of numerous previously screened ASDs in these models [10], and unexpected because focal and secondarily generalized seizures in amygdala kindled rats are typically more difficult to suppress by ASDs than acute seizures in the MES test [14].”
BackgroundResultSelf-citationLöscher, W. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.05.016 · Cited by 164
Self-citationAdjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial
French, J. A., Costantini, C., Brodsky, A., & von Rosenstiel, P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ec7f7f · Cited by 158
New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?
French, J. A., & Gazzola, D. M. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611411127 · Cited by 158
Yates, S. L., Fakhoury, T., Liang, W., Eckhardt, K., Borghs, S., & D'Souza, J. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.09.005 · Cited by 155 · cited 1×
“The more selective SV2A mechanism of brivaracetam versus levetiracetam triggered UCB to perform a small, open-label study to assess if brivaracetam may be associated with fewer behavioral adverse effects [111].”
BackgroundProgress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P., & Perucca, E. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(00)00171-6 · Cited by 152 · cited 2×
“Similar to brivaracetam, a review of levetiracetam [129] has shown linear and time-independent pharmacokinetics, with low intra- and intersubject variability.”
BackgroundMethodGillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148 · cited 2×
“As discussed above, there are different lines of evidence to suggest that modulation of SV2A constitutes the primary mechanism of action of levetiracetam [7, 80], although other effects may contribute to its pharmacodynamic activities.”
BackgroundSelf-citationLevetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?
Klitgaard, H. (2001) · Epilepsia · doi:10.1111/j.1528-1167.2001.00003.x · Cited by 148 · cited 2×
“Indeed, a vast number of studies, conducted at therapeutically relevant concentrations, did not show any direct interaction of levetiracetam with mechanisms through which other ASDs act, including inhibition of sodium and low-voltage activated calcium (T-type) channels [17].”
BackgroundSelf-citationEfficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery
Milligan, T. A., Hurwitz, S., & Bromfield, E. B. (2008) · Neurology · doi:10.1212/01.wnl.0000324624.52935.46 · Cited by 142 · cited 1×
“with phenytoin (36 %), although the difference did not reach statistical significance [148].”
BackgroundVan Vliet, E. A., Aronica, E., Redeker, S., Boer, K., & Gorter, J. A. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01727.x · Cited by 135 · cited 22×
“SV2A expression, measured by Western blotting, was significantly decreased in the temporal neocortex of TLE patients compared with control patients [54].”
BackgroundInfluentialAntiepileptic Drug Development Program: A Cooperative Effort of Government and Industry
Kupferberg, H. J. (1989) · Epilepsia · doi:10.1111/j.1528-1157.1989.tb05815.x · Cited by 133 · cited 1×
“For comparison, levetiracetam was also evaluated in the maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole seizure tests [12], used as initial screens in many ASD discovery programs at that time, including the Anticonvulsant Screening Program (ASP) of the National Institute of Neurological Disorder…”
MethodSurges, R., Volynski, K. E., & Walker, M. C. (2008) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285608094212 · Cited by 129 · cited 1×
“[81] concluded in 2008 that ‘‘although levetiracetam shares some targets with other ASDs, levetiracetam exhibits unique mechanisms of action and a novel and unique binding site’’.”
BackgroundValidation of corneally kindled mice: a sensitive screening model for partial epilepsy in man
Matagne, A., & Klitgaard, H. (1998) · Epilepsy Research · doi:10.1016/s0920-1211(98)00016-3 · Cited by 127 · cited 2×
“Conflict of interest Michel Gillard, Zara Sands, Rafal M. Kaminski, and Henrik Klitgaard are employees of UCB Pharma (Brainel’Alleud, Belgium).”
BackgroundSelf-citationLöscher, W., & Rundfeldt, C. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20238-5 · Cited by 126 · cited 1×
“the phenytoin-resistant amygdala-kindled rat [45].”
Self-citationSynaptic vesicle protein 2A: basic facts and role in synaptic function
Mendoza‐Torreblanca, J. G., Vanoye‐Carlo, A., Phillips‐Farfán, B. V., Carmona‐Aparicio, L., & Gómez‐Lira, G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12360 · Cited by 124 · cited 4×
“SV2A expression has been analyzed in patients experiencing different types of intractable epilepsy, owing to the availability of brain tissue removed from these patients during epilepsy surgery [26].”
BackgroundInfluentialKaminski, R. M., Gillard, M., Leclercq, K., Hanon, E., Lorent, G., Dassesse, D., Matagne, A., & Klitgaard, H. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02089.x · Cited by 116 · cited 5×
“[58] found that SV2A expression in tumor and peritumoral tissue correlated with the efficacy of levetiracetam in postsurgical patients, suggesting an association between SV2A expression and levetiracetam response, an association that has been previously observed [21].”
BackgroundInfluentialSelf-citationProlonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission
Yang, X., Weisenfeld, A., & Rothman, S. M. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2006.01132.x · Cited by 111 · cited 4×
“in brain slices was found to be a reduction in exocytosis [89]; however, the underlying mechanistic effect of ligand binding is not fully elucidated.”
BackgroundInfluentialMeehan, A. L., Yang, X., McAdams, B. D., Yuan, L., & Rothman, S. M. (2011) · Journal of Neurophysiology · doi:10.1152/jn.00279.2011 · Cited by 109 · cited 3×
“shorter when neurons are stimulated [91], suggesting that”
BackgroundBrivaracetam add-on for refractory focal epilepsy: A systematic review and meta-analysis
Lattanzi, S., Cagnetti, C., Foschi, N., Provinciali, L., & Silvestrini, M. (2016) · Neurology · doi:10.1212/wnl.0000000000002545 · Cited by 106 · cited 1×
“It has demonstrated significant efficacy and good tolerability in both phase II and III clinical studies [123, 124] and has recently been approved by the EMA and FDA for this indication.”
BackgroundGenetic Absence Epilepsy in Rats from Strasbourg (GAERS)
Marescaux, C., & Vergnes, M. (1995) · Neurological Sciences · doi:10.1007/bf02229083 · Cited by 103 · cited 1×
“[14], Marescaux and Vergnes [154], Ebert et al.”
BackgroundMagaudda, A., Gélisse, P., & Genton, P. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.56902.x · Cited by 102
Wood, M. D., & Gillard, M. (2017) · Epilepsia · doi:10.1111/epi.13638 · Cited by 101
Self-citationKaminski, R. M., Rogawski, M. A., & Klitgaard, H. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0266-1 · Cited by 97 · cited 2×
“SE, cortical dysplasias, or genetic epilepsy susceptibility [132].”
BackgroundSelf-citationKlein, P., Herr, D., Pearl, P. L., Natale, J. E., Levine, Z. T., Nogay, C., Sandoval, F., Trzcinski, S., Atabaki, S. M., Tsuchida, T. N., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.445 · Cited by 97 · cited 1×
“In one of these studies [145], an open-label, non-randomized study in 126 adults and children, assessing the safety, tolerability, and pharmacokinetics of levetiracetam, treatment in patients with traumatic brain injury (TBI) for 1 month, initiated within 8 h of the injury, showed a non-significant trend toward fewer…”
Antimyoclonic effect of levetiracetam
Genton, P., & Gélisse, P. (2000) · Epileptic Disorders · doi:10.1684/j.1950-6945.2000.tb00445.x · Cited by 96 · cited 1×
“Levetiracetam is also frequently proposed as a treatment opportunity for various types of myoclonus [119], and openlabel trial data even suggested potential antimyoclonic effects in patients with Unverricht–Lundborg disease [120, 121].”
BackgroundLöscher, W., Nau, H., Marescaux, C., & Vergnes, M. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90243-7 · Cited by 95
Self-citationRusso, E., Citraro, R., Scicchitano, F., Fazio, S. D., Paola, E. D. D., Constanti, A., & Sarro, G. D. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02400.x · Cited by 89 · cited 3×
“In spontaneously epileptic rats (SERs), Hanaya et al. [40] found low SV2A expression, particularly in the frontal and entorhinal cortices and the inner molecular layer and dentate gyrus of the hippocampal formation.”
ResultEffects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model
Stratton, S. C., Large, C. H., Cox, B., Davies, G., & Hagan, R. M. (2003) · Epilepsy Research · doi:10.1016/s0920-1211(02)00254-1 · Cited by 89
Evaluation of18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain
Warnock, G. I., Aerts, J., Bahri, M. A., Bretin, F., Lemaire, C., Giacomelli, F., Mievis, F., Mestdagh, N., Buchanan, T., Valade, A., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136143 · Cited by 85
Self-citationYan, H., Ji‐qun, C., Ishihara, K., Nagayama, T., Serikawa, T., & Sasa, M. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.35204.x · Cited by 84
Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A
Nowack, A., Malarkey, E. B., Yao, J., Bleckert, A., Hill, J., & Bajjalieh, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029560 · Cited by 81 · cited 1×
“[92] found that elevated expression of SV2 resulted in a neurotransmission phenotype that resembled that seen in neurons from SV2 knockout mice, suggesting that too much SV2 is as detrimental to neuronal function as too little.”
ResultKindling Increases the Sensitivity of Rats to Adverse Effects of Certain Antiepileptic Drugs
Hönack, D., & Löscher, W. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb01613.x · Cited by 77 · cited 11×
“The first indication that levetiracetam may exert not only anti-seizure activity but also antiepileptogenic or disease-modifying activity came from the study by Löscher et al. [15] in the amygdala-kindling model.”
InfluentialSelf-citationAnticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats
Löscher, W., Reißmüller, E., & Ebert, U. (2000) · Epilepsy Research · doi:10.1016/s0920-1211(00)00108-x · Cited by 76 · cited 1×
“The lack of anti-seizure response in non-responders extended to various other ASDs, with the remarkable exception of the SV2A ligand levetiracetam [47], which suggests that SV2A could be involved in the response of phenytoin non-responders to levetiracetam.”
BackgroundSelf-citationA Systems Level, Functional Genomics Analysis of Chronic Epilepsy
Winden, K. D., Karsten, S. L., Bragin, A., Kudo, L. C., Gehman, L., Ruidera, J., Geschwind, D. H., & Engel, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020763 · Cited by 76 · cited 1×
“[39] found that the network structure and connectivity of the SV2A gene showed significant changes between normal and epileptogenic dentate gyrus, becoming more highly connected in epileptic brain, possibly indicating that SV2A had gained a more important role in synaptic function in epilepsy than under normal conditi…”
BackgroundPearl, P. L., McCarter, R., McGavin, C. L., Yu, Y., Sandoval, F., Trzcinski, S., Atabaki, S. M., Tsuchida, T., van den Anker, J., He, J., et al. (2013) · Epilepsia · doi:10.1111/epi.12326 · Cited by 74
Feng, G., Xiao, F., Lü, Y., Huang, Z., Yuan, J., Xiao, Z., Xi, Z., & Wang, X. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9288-2 · Cited by 74 · cited 22×
“SV2A expression, measured by Western blotting, was significantly decreased in the temporal neocortex of TLE patients compared with control patients [54].”
BackgroundInfluentialSirsi, D., & Safdieh, J. E. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.3.241 · Cited by 73 · cited 1×
“The most serious adverse effects of levetiracetam are behavioral in nature and are more common in children and in adult epilepsy patients with a prior history of behavioral problems and psychiatric disease [110].”
BackgroundMyoclonus: Pathophysiology and Treatment Options
Levy, A., & Chen, R. E. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0404-7 · Cited by 73 · cited 1×
“Levetiracetam is also frequently proposed as a treatment opportunity for various types of myoclonus [119], and openlabel trial data even suggested potential antimyoclonic effects in patients with Unverricht–Lundborg disease [120, 121].”
BackgroundManagement of juvenile myoclonic epilepsy
Crespel, A., Gélisse, P., Reed, R. C., Ferlazzo, E., Jerney, J., Schmitz, B., & Genton, P. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.01.001 · Cited by 71 · cited 1×
“Several randomized, double-blind, placebo-controlled studies in idiopathic generalized epilepsies have shown a significant response of myoclonic seizures to levetiracetam treatment, and the drug is approved by the EMA and FDA as add-on treatment of juvenile myoclonic epilepsy [117, 118].”
BackgroundMadeo, M., Kovács, A. D., & Pearce, D. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.c114.584516 · Cited by 71 · cited 1×
“The latter is supported by homology with the major facilitator superfamily (MFS) of membrane transport proteins [32] and by the suggestion that SV2A is a galactose transporter [33].”
BackgroundBrivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture
Zona, C., Pieri, M., Carunchio, I., Curcio, L., Klitgaard, H., & Margineanu, D. G. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.09.024 · Cited by 71
Self-citation[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A
Estrada, S., Lubberink, M., Thibblin, A., Sprycha, M., Buchanan, T., Mestdagh, N., Kenda, B., Mercier, J., Provins, L., Gillard, M., et al. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.03.004 · Cited by 71
Self-citationLevetiracetam: the first SV2A ligand for the treatment of epilepsy
Klitgaard, H., & Verdru, P. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.11.1537 · Cited by 68 · cited 4×
“Levetiracetam was discovered in 1977 at UCB Pharma in Belgium during research to identify a second-generation nootropic agent to replace piracetam [10]; however, levetiracetam failed to show significant clinical activity in patients with cognitive impairment.”
BackgroundResultInfluentialSelf-citationMercier, J., Archen, L., Bollu, V., Carré, S., Evrard, Y., Jnoff, E., Kenda, B., Lallemand, B., Michel, P., Montel, F., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300482 · Cited by 68
Crèvecœur, J., Kaminski, R. M., Rogister, B., Foerch, P., Vandenplas, C., Neveux, M., Mazzuferi, M., Kroonen, J., Poulet, C., Martin, D., et al. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12054 · Cited by 68 · cited 1×
“[70] studied the expression pattern of all three isoforms of SV2 in the hippocampus of patients with TLE and hippocampal sclerosis.”
BackgroundSelf-citationBialer, M., Twyman, R. E., & White, H. S. (2004) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2004.08.021 · Cited by 65 · cited 1×
“[157], Matagne and Klitgaard [158], Matagne et al.”
BackgroundSynaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma
de Groot, M., Aronica, E., Heimans, J. J., & Reijneveld, J. C. (2011) · Neurology · doi:10.1212/wnl.0b013e318228c110 · Cited by 64 · cited 1×
“[58] found that SV2A expression in tumor and peritumoral tissue correlated with the efficacy of levetiracetam in postsurgical patients, suggesting an association between SV2A expression and levetiracetam response, an association that has been previously observed [21].”
BackgroundDardou, D., Dassesse, D., Cuvelier, L., Deprez, T., Ryck, M. D., & Schiffmann, S. N. (2010) · Brain Research · doi:10.1016/j.brainres.2010.09.063 · Cited by 63 · cited 1×
“SV2C displays an even more restricted pattern of expression, which, under physiological conditions, is mainly limited to basal ganglia and the brain stem [29, 30].”
BackgroundBennett, B. A., Matagne, A., Michel, P., Leonard, M., Cornet, M., Meeus, M.-A., & Toublanc, N. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.014 · Cited by 61 · cited 3×
“more selective for SV2A than levetiracetam [130].”
BackgroundSugaya, Y., Maru, E., Kudo, K., Shibasaki, T., & Kato, N. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.061 · Cited by 60 · cited 1×
“[142] reported that the treatment of rats with levetiracetam over 25 days following SE, induced by intracerebroventricular administration of kainate, reduced the frequency and duration of electrographic seizures recorded 32 days after the termination of treatment [142], which is the first proof that levetiracetam does…”
BackgroundA Mitochondrial Role of SV2a Protein in Aging and Alzheimer’s Disease: Studies with Levetiracetam
Stockburger, C., Miano, D., Baeumlisberger, M., Pallas, T., Arrey, T. N., Karas, M., Friedland, K., & Müller, W. E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150687 · Cited by 60 · cited 1×
“In a cell model for aging and early late-onset AD, levetiracetam improved several aspects of mitochondrial dysfunction, which were abolished when SV2A was knocked down by small interfering RNA (siRNA), indicating that interfering with SV2A at the mitochondrial level, and thereby improving mitochondrial function, might…”
BackgroundPerampanel—new promise for refractory epilepsy?
Löscher, W., & Schmidt, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.222 · Cited by 58 · cited 1×
“Updated and modified from Löscher and Schmidt [151].”
MethodSelf-citationRadiosynthesis of 11C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression
Cai, H., Mangner, T. J., Muzik, O., Wang, M.-W., Chugani, D. C., & Chugani, H. T. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500285t · Cited by 58
Serajee, F., & Huq, A. M. (2015) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2015.02.011 · Cited by 57 · cited 1×
“Recently, the first evidence that an SV2A mutation can cause epilepsy in humans was reported [59].”
BackgroundBretin, F., Bahri, M. A., Bernard, C., Warnock, G., Aerts, J. J., Mestdagh, N., Buchanan, T. J., Otoul, C., Koestler, F., Miévis, F., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0820-6 · Cited by 56
Toering, S. T., Boer, K., De Groot, M., Troost, D., Heimans, J. J., Spliet, W. G. M., Van Rijen, P. C., Jansen, F. E., Gorter, J. A., Reijneveld, J. C., et al. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01955.x · Cited by 56
Gu, J., Lynch, B. A., Anderson, D., Klitgaard, H., Lu, S., Elashoff, M., Ebert, U., Potschka, H., & Löscher, W. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2003.03106.x · Cited by 54 · cited 1×
“After the initial observation of an antiepileptogenic or disease-modifying potential of levetiracetam in the kindling model [15], a gene expression analysis was performed to identify the mechanisms responsible for these effects [137].”
BackgroundSelf-citationHusum, H., Bolwig, T. G., Sánchez, C., Mathé, A. A., & Hansen, S. H. (2004) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2003.12.004 · Cited by 54
Levetiracetam is Not Effective for Essential Tremor
Elble, R. J., Lyons, K. E., & Pahwa, R. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31807a32c6 · Cited by 53
Kälviäinen, R., Genton, P., Andermann, E., Andermann, F., Magaudda, A., Frucht, S. J., Schlit, A., Gerard, D., de la Loge, C., & von Rosenstiel, P. (2016) · Epilepsia · doi:10.1111/epi.13275 · Cited by 53
Mǎrgineanu, D.-G., Matagne, A., Kaminski, R. M., & Klitgaard, H. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.07.006 · Cited by 52 · cited 1×
“[141] reported that, although prophylactic treatment with levetiracetam after a pilocarpine-induced SE did not seem to prevent development of spontaneous seizures, it completely prevented the development of hippocampal hyperexcitability, i.”
BackgroundSelf-citationExpression of SV2 isoforms during rodent brain development
Crèvecœur, J., Foerch, P., Doupagne, M., Thielen, C., Vandenplas, C., Moonen, G., Deprez, M., & Rogister, B. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-87 · Cited by 51
Gingrich, J. A., Andersen, P. H., Tiberi, M., Mestikawy, S. E., Jorgensen, P. N., Fremeau, R. T., & Caron, M. G. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80917-6 · Cited by 51
Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission
Yang, X., & Rothman, S. M. (2009) · Seizure · doi:10.1016/j.seizure.2009.07.004 · Cited by 51 · cited 1×
“ther studies showed that levetiracetam decreased vesicular release in a dose-, time-, and stimulation-dependent manner, suggesting that repetitive stimulation is required to allow levetiracetam entry into recycling synaptic vesicles and intravesicular levetiracetam binding to SV2A [90].”
BackgroundHanaya, R., Hosoyama, H., Sugata, S., Tokudome, M., Hirano, H., Tokimura, H., Kurisu, K., Serikawa, T., Sasa, M., & Arita, K. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.06.058 · Cited by 49
Upreti, C., Otero, R., Partida, C., Skinner, F., Thakker, R., Pacheco, L. F., Zhou, Z.-Y., Maglakelidze, G., Velíšková, J., Velíšek, L., et al. (2012) · Brain · doi:10.1093/brain/awr341 · Cited by 48 · cited 20×
“SV2A expression, measured by Western blotting, was significantly decreased in the temporal neocortex of TLE patients compared with control patients [54].”
BackgroundInfluentialBrivaracetam augments short‐term depression and slows vesicle recycling
Yang, X., Bognar, J., He, T., Mohammed, M., Niespodziany, I., Wolff, C., Esguerra, M., Rothman, S. M., & Dubinsky, J. M. (2015) · Epilepsia · doi:10.1111/epi.13223 · Cited by 47
Levetiracetam prevents kindling‐induced asymmetric accumulation of hippocampal 7S SNARE complexes
Matveeva, E. A., Vanaman, T. C., Whiteheart, S. W., & Slevin, J. T. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01687.x · Cited by 45 · cited 2×
“[42] reported that the ipsilateral accumulation of SV2s in the hippocampus persists for at least”
BackgroundThe effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis
Feys, P., D'hooghe, M. B., Nagels, G., & Helsen, W. F. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458508099142 · Cited by 45
Russo, E., Mumoli, L., Palleria, C., Gasparini, S., Citraro, R., Labate, A., Ferlazzo, E., Gambardella, A., & Sarro, G. D. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s81474 · Cited by 45 · cited 1×
“potency over levetiracetam for protection of both generalized and partial seizures [8, 80, 100].”
BackgroundBankstahl, M., Bankstahl, J. P., & Löscher, W. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2013.09.014 · Cited by 44 · cited 2×
“[50] applied this model in mice that had been rendered epileptic by a pilocarpine-”
BackgroundMethodSelf-citationPreclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H
Bretin, F., Warnock, G., Bahri, M. A., Aerts, J., Mestdagh, N., Buchanan, T., Valade, A., Mievis, F., Giacomelli, F., Lemaire, C., et al. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-35 · Cited by 43 · cited 1×
“Recently, [(18)F]UCB-H, a high-affinity PET ligand for SV2A, was developed [73, 74].”
BackgroundTherapeutic advances in tremor
Fasano, A., & Deuschl, G. (2015) · Movement Disorders · doi:10.1002/mds.26383 · Cited by 43 · cited 1×
“The latter seems of particular interest as case reports [102] and open-label observations [103] have suggested potential anti-tremor activity of levetiracetam in some tremor types, although this has not been confirmed by double-blind, placebo controlled trials [104–107].”
BackgroundVenkatesan, K., Alix, P., Marquet, A., Doupagne, M., Niespodziany, I., Rogister, B., & Seutin, V. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23111 · Cited by 42 · cited 1×
“Furthermore, both the frequency and amplitude of spontaneous excitatory and inhibitory postsynaptic currents is not significantly altered in SV2B knockout mice [69].”
Backgroundde Groot, M., Toering, S. T., Boer, K., Spliet, W. G. M., Heimans, J. J., Aronica, E., & Reijneveld, J. C. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop028 · Cited by 42 · cited 4×
“Modest SV2A IR was observed within the tumor area [57].”
BackgroundInfluentialAsymmetric accumulation of hippocampal 7S SNARE complexes occurs regardless of kindling paradigm
Matveeva, E. A., VANAMAN, T. C., Whiteheart, S. W., & Slevin, J. T. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.11.003 · Cited by 42 · cited 1×
“8 s) unilateral stimulations of the amygdala, entorhinal cortex or septum, the expression of synaptosomal SV2s (SV2A/SV2B) in the ipsilateral hippocampus significantly increased, regardless of the stimulation site [41].”
BackgroundOhno, Y., Ishihara, S., Terada, R., Kikuta, M., Sofue, N., Kawai, Y., Serikawa, T., & Sasa, M. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.035 · Cited by 41 · cited 2×
“An increase in hippocampal SV2A expression was also observed in mice kindled by repeated administration of pentylenetetrazole [43, 44].”
BackgroundResults of phase II pharmacokinetic study of levetiracetam for prevention of post‐traumatic epilepsy
Klein, P., Herr, D., Pearl, P. L., Natale, J. E., Levine, Z. T., Nogay, C., Sandoval, F., Trzcinsky, S., Atabaki, S. M., Tsuchida, T. N., et al. (2012) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2012.05.011 · Cited by 41
Correa-Basurto, J., Cuevas-Hernández, R. I., Phillips-Farfán, B. V., MartÃnez-Archundia, M., Romo-Mancillas, A., RamÃrez-Salinas, G. L., Pérez-González, Ã. A., Trujillo-Ferrara, J., & Mendoza-Torreblanca, J. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00125 · Cited by 40 · cited 1×
“[87] built a complete model of the SV2A protein with levetiracetam, along with other racetams (brivaracetam and seletracetam) docked into it.”
BackgroundProfile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy
Matagne, A., Mǎrgineanu, D.-G., Potschka, H., Löscher, W., Michel, P., Kenda, B., & Klitgaard, H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.04.024 · Cited by 39 · cited 2×
“6 L/kg, and plasma terminal half-life was approximately 8 h in young healthy male subjects [131].”
BackgroundSelf-citationBragina, L., Fattorini, G., Giovedí, S., Melone, M., Bosco, F., Benfenati, F., & Conti, F. (2012) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2011.00032 · Cited by 39 · cited 1×
“It appears that SV2B levels are very low in the synaptic vesicles of GABAergic neurons compared with SV2A, and appear to have a preferential localization in glutamatergic neurons [67].”
BackgroundA role for Sv2c in basal ganglia functions
Dardou, D., Monlezun, S., Foerch, P., Courade, J., Cuvelier, L., Ryck, M. D., & Schiffmann, S. N. (2013) · Brain Research · doi:10.1016/j.brainres.2013.02.041 · Cited by 38 · cited 1×
“Interestingly, SV2C mRNA expression was also significantly increased in the striatum of animals challenged with 6-hydroxydopamine, a model of Parkinson’s disease [72].”
BackgroundVisualization of SV2A conformations in situ by the use of Protein Tomography
Lynch, B. A., Matagne, A., Brännström, A., von Euler, A., Jansson, M., Hauzenberger, E., & Söderhäll, J. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.145 · Cited by 37 · cited 1×
“Structural evidence for this eventually came from protein tomography experiments [84].”
BackgroundAntiepileptogenic and anticonvulsive actions of levetiracetam in a pentylenetetrazole kindling model
Ohno, Y., Ishihara, S., Terada, R., Serikawa, T., & Sasa, M. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.01.011 · Cited by 37 · cited 1×
“Furthermore, levetiracetam, but not valproate, was found to suppress pentylenetetrazole kindling at doses that did not suppress pentylenetetrazole-induced seizures [136].”
BackgroundA Numbering System for MFS Transporter Proteins
Lee, J., Sands, Z. A., & Biggin, P. C. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00021 · Cited by 37 · cited 1×
“Models of b inward-open (based on GlpT template) and c outward-open (based on FucP) conformations of the SV2A protein [86] aligned using the numbering system for proteins of the major facilitator superfamily [153].”
MethodSelf-citationDetrait, E., Maurice, T., Hanon, É., Leclercq, K., & Lamberty, Y. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.06.013 · Cited by 35
Niquet, J., Suchomelova, L., Thompson, K., Klitgaard, H., Matagne, A., & Wasterlain, C. (2017) · Epilepsia · doi:10.1111/epi.13787 · Cited by 35
Self-citationLevetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking
García‐Pérez, E., Mahfooz, K., Covita, J., Zandueta, A., & Wesseling, J. F. (2015) · Epilepsia · doi:10.1111/epi.12930 · Cited by 34
Shi, J., Anderson, D., Lynch, B. A., Castaigne, J.-G., Foerch, P., & Lebon, F. (2011) · Biochemical Society Transactions · doi:10.1042/bst0391341 · Cited by 33 · cited 3×
“[85], the outward-open conformation of SV2A (i.”
BackgroundMethodInfluentialTargeting SV2A for discovery of antiepileptic drugs
Kaminski, R. M., Gillard, M., & Klitgaard, H. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02869.x · Cited by 33 · cited 2×
“As discussed above, there are different lines of evidence to suggest that modulation of SV2A constitutes the primary mechanism of action of levetiracetam [7, 80], although other effects may contribute to its pharmacodynamic activities.”
BackgroundSelf-citationLevetiracetam in primary orthostatic tremor: A double‐blind placebo‐controlled crossover study
Hellriegel, H., Raethjen, J., Deuschl, G., & Volkmann, J. (2011) · Movement Disorders · doi:10.1002/mds.23881 · Cited by 32
Axon glycoprotein routing in nerve polarity, function, and repair
Abad‐Rodríguez, J., & Díez‐Revuelta, N. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.03.015 · Cited by 32
Levetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?
Klitgaard, H. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.0420s4013.x · Cited by 32
Self-citationTargeting SV2A for Discovery of Antiepileptic Drugs
Kaminski, R. M., Gillard, M., & Klitgaard, H. (2012) · Jasper's Basic Mechanisms of the Epilepsies · doi:10.1093/med/9780199746545.003.0076 · Cited by 31
Self-citationLevetiracetam may favorably affect seizure outcome after temporal lobectomy
Jehi, L. E., Irwin, A., Kayyali, H., Vadera, S., Bingaman, W. E., & Najm, I. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03453.x · Cited by 30 · cited 1×
“ASD use in patients who underwent temporal lobectomy demonstrated perioperative use of levetiracetam to predict a more favorable outcome [149].”
BackgroundEbert, U., Reißmüller, E., & Löscher, W. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00039-3 · Cited by 30 · cited 1×
“[155], Hönack and Löscher [156], Barton et al.”
Self-citationLee, J., Daniels, V., Sands, Z. A., Lebon, F., Shi, J., & Biggin, P. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116589 · Cited by 29 · cited 4×
“[86], wherein they considered two conformational states based on two additional templates: L-fucose-proton symporter as a template for the outwardopen state, and Glycerol-3-phosphate transporter as a template for the inward-open state (Figs.”
BackgroundMethodInfluentialSelf-citationDaniels, V, Wood, M., Leclercq, K., Kaminski, R. M., & Gillard, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12192 · Cited by 28 · cited 5×
“that ligand binding to SV2A would promote/stabilize a conformation that enables the protein to fulfill a role in providing seizure protection [88].”
BackgroundInfluentialSelf-citationWang, L., Shi, J., Wu, G., Zhou, F., & Hong, Z. Y. (2014) · Epilepsy Research · doi:10.1016/j.eplepsyres.2014.07.005 · Cited by 28 · cited 2×
“[48] selected phenytoin- and phenobarbital-resistant rats from a large”
BackgroundKindling-associated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus
Ohno, Y., Okumura, T., Terada, R., Ishihara, S., Serikawa, T., & Sasa, M. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.01.009 · Cited by 26 · cited 4×
“An increase in hippocampal SV2A expression was also observed in mice kindled by repeated administration of pentylenetetrazole [43, 44].”
BackgroundInfluentialSuccessful treatment of Holmes tremor by levetiracetam
Ferlazzo, E., Morgante, F., Rizzo, V., Sciarrone, G. J., Meduri, M., Magaudda, A., Girlanda, P., & Quartarone, A. (2008) · Movement Disorders · doi:10.1002/mds.22230 · Cited by 25
Profile of brivaracetam and its potential in the treatment of epilepsy
Ferlazzo, E., Russo, E., Mumoli, L., Sueri, C., Gasparini, S., Palleria, C., Labate, A., Gambardella, A., Sarro, G. D., & Aguglia, U. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s60849 · Cited by 20
Brivaracetam for the treatment of epilepsy
Klein, P., Tyrlíková, I., Brázdil, M., & Rektor, I. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1135129 · Cited by 20 · cited 1×
“It has demonstrated significant efficacy and good tolerability in both phase II and III clinical studies [123, 124] and has recently been approved by the EMA and FDA for this indication.”
BackgroundBuckmaster, P. S., Yamawaki, R. M., & Thind, K. K. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4049-15.2016 · Cited by 17 · cited 20×
“SV2A expression, measured by Western blotting, was significantly decreased in the temporal neocortex of TLE patients compared with control patients [54].”
BackgroundInfluentialCommentary: A Skeptical View of Experimental Gene Therapy to Block Epileptogenesis
Dudek, F. E. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.01.020 · Cited by 16 · cited 1×
“The only other ASD, for which a similar effect had been described previously, was high-dose treatment with valproate [133], whereas other ASDs just retarded kindling by their suppressive effect on kindled seizures [134].”
BackgroundAntiepileptogenesis Therapy with Levetiracetam: Data from Kindling versus Status Epilepticus Models
Dudek, F. E., Bertram, E. H., & Staley, K. J. (2007) · Epiliepsy currents/Epilepsy currents · doi:10.1111/j.1535-7511.2007.00226.x · Cited by 16
Leclercq, K., & Kaminski, R. M. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.06.011 · Cited by 15 · cited 4×
“induced SE, and observed that levetiracetam was much more effective in blocking 6-Hz seizures in epileptic mice rather than non-epileptic mice, which was substantiated by Leclercq and Kaminski [51].”
BackgroundResultInfluentialSelf-citationRole of levetiracetam in the treatment of epilepsy
Brodie, M. J., & French, J. A. (2003) · Epileptic Disorders · doi:10.1684/j.1950-6945.2003.tb00033.x · Cited by 14 · cited 1×
“In subsequent years, several clinical studies confirmed the efficacy and safety of levetiracetam, and the drug became the most prescribed newer generation ASD for the treatment of epilepsy [18].”
BackgroundMechanisms of Action of Levetiracetam and Newer SV2A Ligands
Klitgaard, H., & Matagne, A. (2009) · Blue books of neurology · doi:10.1016/b978-1-4160-6171-7.00003-0 · Cited by 7
Self-citationDoes levetircetam decrease of the rubral tremor in patients with multiple sclerosis.
Chitsaz, A., Mehrbod, N., Etemadifar, M., & Najafi, M. (2013) · PubMed Central · Cited by 5
Laruelle, M. A., Detrait, E., Lamberty, Y., Leclercq, K., Jnoff, E., Wood, M., Gillard, M. R., Jigorel, É., Klitgaard, H., & Provins, L. (2014) · Schizophrenia Research · doi:10.1016/s0920-9964(14)70213-0 · Cited by 3
Self-citationChung, S. S., Klein, P., Sperling, M. R., Diaz, A., Elmoufti, S., Schiemann, J., & Whitesides, J. (2016) · Neurology · doi:10.1212/wnl.86.16_supplement.p2.027 · Cited by 3
Swallow, E., Fang, A., Signorovitch, J., Plumb, J., & Borghs, S. (2016) · Value in Health · doi:10.1016/j.jval.2016.03.182 · Cited by 2 · cited 1×
“increasing refractoriness, increasing placebo response rates over time) [125].”
BackgroundWood, M. D., & Gillard, M. R. (2016) · Neurology · doi:10.1212/wnl.86.16_supplement.p5.246 · Cited by 2
Self-citation
Research works printed but not linked: 2
- Crèvecoeur J, Kaminski R, Rogister B, et al. Expression of synaptic vesicle protein 2C (SV2C) is selectively increased in hippocampal sclerosis with mossy fiber sprouting. Eur J Neurol. 2011;18(Suppl. 2):175.
- Wasterlain C, Suchomelova L, Matagne A, et al. Short-term and long-term effects of brivaracetam in an animal model of status epilepticus. Epilepsia. 2009;50(Suppl. 10):13.
Cited by
Löscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367
“The finding of Löscher and Hönack [32] that levetiracetam is particularly effective in the amygdalakindling model was essential in the further development of this compound, which is now one of the most widely used ASMs [33].”
BackgroundSelf-citationThe Concise Guide to PHARMACOLOGY 2023/24: Transporters
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16182 · Cited by 163
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16725 · Cited by 148
Löscher, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.730257 · Cited by 153
“However, the typical approach of ASM testing in animal models primarily focuses on drug potency, and not efficacy (Löscher, 2016).”
BackgroundInfluentialSelf-citationThe holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments
Löscher, W. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.011 · Cited by 137
Self-citation
Metadata
- Authors
- Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H.
- Affiliations
- University of Veterinary Medicine Hannover, Foundation (DE)
- UCB Pharma (Belgium) (BE)
- Corresponding author
- Löscher, Wolfgang
- Venue
- CNS Drugs
- Published
- 2016-10-17
- Volume
- 30
- Issue
- 11
- Pages
- 1055-1077
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC5078162
- OpenAlex
- W2539233923
- Cited by
- 184
- References
- 163
- Citations by year
- 2026: 20 · 2025: 23 · 2024: 20 · 2023: 12 · 2022: 17 · 2021: 29 · 2020: 20 · 2019: 21 · 2018: 10 · 2017: 11
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Keywords
- SV2A, levetiracetam, epilepsy, major facilitator superfamily, vesicle trafficking, exocytosis, neurotransmission, procognitive effects, Alzheimer's disease, cognitive impairment, SV2B, SV2C, druggable targets, antiepileptic drugs
- MeSH terms
- Animals, Anticonvulsants, Epilepsy, Humans, Ligands, Membrane Glycoproteins, Synaptic Vesicles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.